Isomorphic Labs, a 2021 spinoff of Google DeepMind, is 'very close' to launching human clinical trials for its AI-designed drugs, as stated by president Colin Murdoch.
The drugs are being developed using AlphaFold technology for predicting protein structures and designing medicines faster and more accurately, targeting areas like cancer.
Murdoch highlighted ongoing work in London offices collaborating with AI on cancer drugs, with the company staffing up for trials.
Isomorphic has partnerships with Novartis and Eli Lilly, raised $600 million in April 2025, and aims to improve drug success rates and eventually design drugs on demand.
News reported in July 2025 by Fortune, Slashdot, Cybernews, and The News.